Background: In most institutions, locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy followed by surgery 6e8 weeks later, allowing time for tumor response and recovery from chemoradiotherapy-related toxicities. In our hospital, we continuously administer chemotherapy after the completion of chemoradiotherapy, until 2 weeks before surgery for most patients. Methods: This was a retrospective study. Patients received a diagnosis of adenocarcinoma of the rectum at our hospital between January 2003 and December 2008 and received neoadjuvant chemoradiotherapy and curative surgery. Chemoradiotherapy consisted of continuous infusion of 225 mg/m 2 5-fluorouracil, 5 days per week. Radiation therapy was delivered at 1.8 Gy per day, 5 days per week for 5e6 weeks (median radiation dose, 50.4 Gy). Chemotherapy was continued until 2 weeks before surgery, and surgery was performed 6e8 weeks after completion of chemoradiotherapy. Results: The study included 119 patients (median age, 61 years; range, 24e84 years). Twenty-nine patients (24.4%) had a complete response and 65 (54.6%) had a partial response. Over a median follow-up duration of 52 months, 10 patients experienced local recurrence and 18 had distant metastasis. The 5-year overall and disease-free survival rates were 80.6% and 72.9%, respectively. Grade 3e4 toxicity only occurred in 14 patients (11.8%). Conclusion: Continued chemotherapy with 5-fluorouracil after completing neoadjuvant chemoradiotherapy until 2 weeks before surgery for locally advanced rectal cancer results in a good pathological control rate, with low toxicity. Patients who achieved a complete pathological response had a better long-term oncological outcome than those who did not.
Introduction
Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is an important treatment strategy for locally advanced rectal cancer (defined as T3 or nodepositive rectal cancer). Preoperative CRT is associated with a lower local recurrence rate and general toxicities than postoperative CRT.
1e3 Neoadjuvant CRT usually results in a reduced tumor size, increased tumor mobility, and histopathologic downstaging, with correspondingly improved long-term oncologic outcomes. 4 Approximately 15e20% of patients have a pathological complete response (pCR) at the time of surgery, 5e7 although the likelihood of a pCR may be related to
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In most institutions, locally advanced rectal cancer is generally treated with neoadjuvant CRT followed by surgery, 6e8 weeks later, to allow for a tumor response to CRT and recovery from CRT-related toxicity. In our hospital, we continue to administer chemotherapy after the completion of CRT until 2 weeks before surgery for locally advanced rectal cancer. Here, we report the oncological outcome, pathological complete response rate, and toxicities associated with this strategy.
Methods

Data source
We retrospectively reviewed the medical records of patients in whom adenocarcinoma of the rectum was diagnosed (tumor located within 12 cm from the anal verge) who received neoadjuvant CRT in our hospital between January 2003 and December 2008. Patients with tumor metastasis or unresectable tumors, those who only underwent local excision, and those who achieved a clinical complete response under observation alone were excluded. The rectal adenocarcinoma diagnosis was based on sigmoidoscopy biopsy. T staging was scored by transrectal ultrasonography or magnetic resonance imaging (MRI), and N staging was scored by pelvic computed tomography (CT). Distant metastasis was evaluated using an abdominal CT scan and chest X-ray film for all patients. Clinical data including age, sex, Eastern Cooperative Oncology Group performance status, operative method, tumor recurrence, tumor distance from the anal verge, pretreatment clinical tumor stage and size, histologic grade, radiotherapy dose, chemotherapy toxicities, preoperative clinical stage, postoperative pathological stage, site of tumor recurrence, survival status, and duration of follow-up were analyzed.
The treatment program is shown in Fig. 1 . All patients were treated with 5-fluorouracil (5-FU) continuous infusion at a dose of 225 mg/m 2 , 5 days per week, concurrent with radiotherapy. Radiation therapy was delivered at 1.8 Gy per day, 5 days per week for 5e6 weeks, and the median radiation dose was 50.4 Gy (range, 43.2e65.5 Gy). Chemotherapy was continued until 2 weeks before surgery, and the patient underwent surgery within 6e8 weeks after finishing radiotherapy. The clinical response was evaluated by post-CRT CT, sigmoidoscopy, and digital rectal examination. After surgery, planned adjuvant treatment was a 5-FU based chemotherapy regimen.
Statistical analyses
We compared the general characteristics between groups with and without pCR. We analyzed differences with respect to specific clinical factors according to whether patients had a complete response using Student t test, Yates' correction and Fisher's exact test. We compared the recurrence rate between groups with and without pCR using Fisher's exact test.
Overall survival was defined as the time from the beginning of CRT to the date of the last follow-up visit or death. Diseasefree survival was defined as the time from surgery to the date of death, last follow-up visit, or treatment failure (local or distant recurrence). Local recurrence was defined as tumor recurrence in the pelvis, perineum, or anastomosis site. Distant metastasis was defined as tumor recurrence outside the pelvis. The follow-up duration was defined as the time from surgery to the last follow-up visit or any type of event. We used the KaplaneMeier survival method to compare disease-free and overall survival for patients with and without pCR, and logrank test to identify significant differences. All analyses were performed using GraphPad Prism Version 5 (GraphPad Software, San Diego, CA, USA). A p value <0.05 was considered statistically significant.
Results
Between January 2003 and December 2008, 127 patients were included in our study; eight patients did not complete the full course of CRT (6 due to CRT intolerance and 2 due to disease progression during CRT). Finally, a total of 119 patients were included in the analysis. The characteristics of all 119 patients are summarized in Table 1 . Seventy-four patients were men and 45 were women, with a median age of 61 years (range, 24e84 years). Thirty-six patients (30.3%) underwent transrectal ultrasonography for clinical T staging and 83 (69.7%) underwent MRI for clinical T staging. The preoperative clinical stage of the patients was stage II in 41 cases (34.5%) and stage III in 78 cases (65.5%), and the median tumor size was 2.8 cm (range, 0.8e12 cm). After neoadjuvant CRT, all patients underwent surgery, which involved lower anterior resection in 81 cases (31 cases with protective ileostomy), abdominoperineal resection in 37 cases, and Hartmann procedure in one case. Of 67 patients with a low rectal tumor patients (79%). Twenty-nine patients (24.4%) had a complete response and 65 (54.6%) had a partial response. Upstaging occurred in five patients after surgery. Of the 29 patients with complete response, 21 (72.4%) received adjuvant chemotherapy. Of the 90 patients with no complete response, 80 (88.9%) received adjuvant chemotherapy. Of the 101 patients who received adjuvant chemotherapy, 94 (93.1%) completed the planned number of treatment cycles.
The median follow-up time was 52 months (range, 7e100 months), during which local recurrence occurred in 10 (8.4%) patients and distant metastasis occurred in 18 (15.1%). The 5-year overall and disease-free survival rates were 80.6% and 72.9%, respectively. Four patients had concomitant local recurrence and distant metastasis.
As shown in Table 2 , neither age (
, nor histologic type ( p ¼ 0.405) were significantly different between patients who did or did not achieve a complete response.
Fewer patients who achieved a complete response had local recurrence (0% vs. 11.1%, p ¼ 0.116), distant metastasis (0% vs. 20%, p ¼ 0.006) or any type of recurrence (0% vs. 26.7%, p ¼ 0.001) compared to those who failed to achieve a complete response (Table 3 ). The 5-year disease-free survival rate was 96.6% for the pCR group and 65.6% for the non-pCR group [hazard ratio (HR): 5.306; 95% confidence interval (CI): 1.283e6.202; p ¼ 0.009; Fig. 2 ]. The 5-year overall survival rate was 96.6% for the pCR group and 75.8% for the non-pCR group (HR: 2.379; 95%CI: 0.634e6.507; p ¼ 0.069; Fig. 3 ).
Toxicity
The toxicity events are listed in Table 4 . The most common adverse events related to CRT were leukopenia (30.3%) and diarrhea (25.2%). Overall, Grade 3e4 toxicities developed in 14 patients (11.8%), of whom Grade 4 leukopenia developed in one, Grade 4 diarrhea in one, Grade 3 leukopenia in six, Grade 3 diarrhea in one, Grade 3 anemia in two, a Grade 3 dermatologic complication in two, and Grade 3 vomiting in one. 
Discussion
Currently, neoadjuvant CRT with 5-FU is widely used for treating locally advanced rectal cancer in order to achieve tumor downstaging and shrinkage, thereby increasing the likelihood of curative surgical resection and reducing the risk of local recurrence. 8, 9 Many studies have found that patients with pCR after CRT are less likely to have local or distant recurrence, and survive for longer than those with noncomplete response.
10e12 Therefore, conventional CRT has been modified in a number of studies, for example, by including additional chemotherapeutic agents, extending the interval between CRT and surgery, and adding continued chemotherapy in the period between CRT and surgery. Additional chemotherapeutic agents that have been studied in this context include oxaliplatin 13, 14 and cetuximab. 15, 16 These resulted in a pCR rate of 8e19%, which is lower than the 24.4% observed in our study. Although adding irinotecan 17 resulted in a higher pCR rate of 26%, the incidence of acute Grade 3e4 toxicity was as high as 42%, and hence, this therapy cannot be well tolerated by most patients. None of these studies convincingly showed that adding these Data are presented as n (%).
chemotherapy agents can improve the pCR, and the combination of two or more chemotherapy agents may result in higher toxicity rates and a higher cost. The results of additional chemotherapy during the resting period after CRT have also been reported. Garcia-Aguilar et al 18 reported a nonrandomized prospective trial comparing one group of patients who underwent CRT consisting of 5-FU followed by surgery 6 weeks later, with another group treated with an additional two cycles of modified FOLFOX-6 in the 4 weeks following the completion of CRT and then surgery 3e5 weeks later. This study concluded that additional chemotherapy after CRT was well tolerated and may increase the pCR rate (18% vs. 25%), although this difference was not statistically significant. Furthermore, surgery was delayed for patients undergoing additional chemotherapy, and it is therefore possible that the increased pCR rate was actually attributable to a longer CRT-to-surgery interval. The oncological outcome was also not reported in this study.
Another additional chemotherapy regimen after CRT completion, investigated by Habr-Gama et al, 19 consisted of three extra cycles of bolus 5-FU. Their study included 29 patients, of whom 14 (48%) had a clinical complete response for at least 12 months and five (17%) had ypT0 after local excision. The overall complete response rate was 65%. However, none of the patients underwent TME, and occult cancer might not have been detected during the median follow-up period of 24 months. Another complication is that 17% of patients had stage I disease, which may have contributed to the high pCR rate.
In our study, continuously administered chemotherapy with 5-FU after the completion of radiotherapy until 2 weeks before surgery for locally advanced rectal cancer resulted in a pCR rate of 24.4%, which is higher than that obtained using conventional 5-FU-based CRT (15e20%). 5e7 The high pCR rate might be attributable to the prolonged exposure of irradiated tumor cells to chemotherapy. Furthermore, only 14 patients (11.8%) experienced Grade 3e4 toxicity and most tolerated the treatment well, with good treatment compliance. When compared to adding chemotherapeutic agents to CRT, such as oxaliplatin 14 or irinotecan, 17 which resulted in an incidence of Grade 3e4 toxicity >20%, the toxicity associated with our approach was more tolerable.
In the current study, the 5-year disease-free survival rate (96.6% vs. 65.6%, p ¼ 0.009) and 5-year overall survival rate (96.6% vs. 75.8%, p ¼ 0.069) were higher in the complete response group than in the noncomplete response group. Several previous studies reported that patients with a pCR after CRT had better long-term outcomes than those who did not achieve a pCR, 10e12 although another study found similar outcomes between these patient groups. 20 Our study also confirmed that patients with a pCR more often achieved 5-year disease free and overall survival. Overall survival did not differ significantly between pCR and non-pCR groups in our study, which might be due to the higher median age (61 years) and the relatively small size of the former group. The local recurrence rate, distant metastasis rate, and overall recurrence rate were lower in pCR group. These findings further support the importance of achieving a pCR in order to improve longterm oncological outcome.
There are a number of limitations to our study. First, although the pCR rate was higher in our study than in most studies reported in the literature, the benefit of the continued chemotherapy was difficult to interpret because of the absence of a control group. Second, owing to the retrospective design of the study, it is possible that some data were missing and that some cases of disease relapse had not been recorded because of poor communication. Furthermore, the radiation dose and chemotherapy dose cannot be well controlled in a retrospective study. Finally, the study had only a small sample size. A multicenter randomized prospective study is needed to validate our findings.
In conclusion, continued chemotherapy with 5-FU after the completion of neoadjuvant CRT until 2 weeks before curative surgery for locally advanced rectal cancer results in only a low level of toxicity and a good pCR rate. Patients who had a pCR after CRT had better long-term oncological outcomes.
